✨ Your Portfolio is fetched and updated from zerodha.
Market Cap
₹13,272 Cr.
P/E
26.97
About
Granules India Limited, a vertically integrated pharmaceutical manufacturing company based in Hyderabad, India, specializes in producing APIs, PFIs, and FDs. Known for its product-focused business mod… Read more
Granules India Limited, a vertically integrated pharmaceutical manufacturing company based in … Read more
Low
319
52W Range
High
721
Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max

Company Timeline

Custom financial statement
Edit rows
Forensics

11 Yes

Positive for this company

1 Neutral

Neutral for this company

5 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Segment Break-Up

Location Wise Break-Up

Operational Metrics

    Select a Metric
    • US DMF Filings (.)
    • Europe DMF Filings (.)
    • Manufacturing Capacity - Metformin (MTPA)
    • Manufacturing Capacity - Ibuprofen (MTPA)
    • Total reactor capacity (kL)
    • Manufacturing Capacity - Paracetamol (MTPA)
    • Number of ANDA's Approved By USFDA (.)
    • Number of ANDA's Filed in USA (.)
    • Number of ANDA's Filed (.)
    • Number of ANDA's Approved (.)
    • R&D as a % of Total Sales (%)
    Peer Comparison
    Suppliers
    • IOL Chemicals And Pharmaceuticals Ltd.
    FAQs on Granules India Ltd. Business

    Granules India Limited is a high-growth pharmaceutical company in India, specializing in APIs, PFIs, and FDs. It holds a leadership position in generic drugs like Paracetamol and Ibuprofen.

    Granules India major competitors are Solara Active Pharma, IOL Chem & Pharma, Glenmark Life Scienc, Neuland Laboratories, Shilpa Medicare, AMI Organics, Aarti Pharmalabs.
    Market Cap of Granules India is ₹13,454 Crs.
    While the median market cap of its peers are ₹6,184 Crs.

    Granules India seems to be less financially stable compared to its competitors.
    Altman Z score of Granules India is 5.78 and is ranked 5 out of its 8 competitors.

    Company Filing
    2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Investor Presentation Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call SummaryCon Call Summary Sep Mar Jun Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Discussions & Analysis